EXECUTIVE SEVERANCE AGREEMENTExecutive Severance Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This EXECUTIVE SEVERANCE AGREEMENT (the “Agreement”) is entered into by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia” or the “Company”), and _________________, a resident of _________________________________ (the “Executive”), and is effective as of ____________ (the “Effective Date”).
AKEBIA THERAPEUTICS, INC. STOCK OPTION AGREEMENT FOR OFFICERSStock Option Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Akebia Therapeutics, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2023 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof.
AKEBIA THERAPEUTICS, INC. OFFICER INDUCEMENT AWARD STOCK OPTION AGREEMENTOfficer Inducement Award Stock Option Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Akebia Therapeutics, Inc. (the “Company”) hereby grants the following inducement non-statutory stock option award. The terms and conditions attached hereto are also a part hereof.
AKEBIA THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT FOR OFFICERSRestricted Stock Unit Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Date] Personal and Confidential [First Name Last name] [Address] Re: ELT Special Bonus Program Dear [First Name Last name]:Bonus Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGREEMENT FOR THE...Loan Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
KREOS CAPITAL VII (UK) LIMITED, a company incorporated in England and Wales under registration number 13611522 whose registered office is at 25-28 Old Burlington Street, London W1S 3AN, as a Lender (the "Lender Representative", which expression shall include its permitted successors and permitted assigns);
WARRANT AGREEMENTWarrant Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS WARRANT AGREEMENT (this “Agreement”), is made and entered into as of January 29, 2024 (the “Effective Date”), by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and Kreos Capital VII Aggregator SCSp (“Holder”).
February 7, 2024 BY EMAIL Michel DahanSeparation Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Upon your execution of this Amendment, the following amendments will be made to your Separation Agreement with Akebia Therapeutics, Inc. (“Akebia”) dated May 5, 2022 (as previously amended, the “Separation Agreement”). Paragraph 1(ii) of the Separation Agreement shall be replaced in its entirety with the following:
February 8, 2024 BY EMAILSeparation Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
Upon your execution of this Amendment, the following amendments will be made to your Separation Agreement with Akebia Therapeutics, Inc. (“Akebia”) dated May 5, 2022 (as previously amended, the “Separation Agreement”). Paragraph 1(ii) of the Separation Agreement shall be replaced in its entirety with the following:
FOURTH AMENDMENT TO LOAN AGREEMENTLoan Agreement • March 14th, 2024 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
This FOURTH AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated and effective as of October 31, 2023 (the “Fourth Amendment Effective Date”), by and among AKEBIA THERAPEUTICS, INC., a Delaware corporation (as “Borrower”), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales (as a “Lender”), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership (as a “Lender”).
